Group 1 - The core index of the China Securities Index for Food and Major Consumer Goods Retail has shown a recent upward trend, with a 4.43% increase over the past month, a 0.49% increase over the past three months, and a year-to-date decline of 3.88% [1] - The index is composed of listed companies in the food and drug retail sector, reflecting the overall performance of these companies, with a base date of December 31, 2004, set at 1000.0 points [1] - The top ten weighted companies in the index include Yonghui Supermarket (6.49%), Digital China (6.34%), Shanghai Pharmaceuticals (4.65%), Yifeng Pharmacy (4.23%), and others [1] Group 2 - The market share of the index's holdings is divided between the Shanghai Stock Exchange (53.16%) and the Shenzhen Stock Exchange (46.84%) [1] - In terms of industry composition, the index shows that pharmaceutical commerce accounts for 44.64%, supermarkets and convenience stores for 20.60%, specialty retail for 20.32%, and department stores for 14.44% [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December each year [2]

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 文/新浪财经上海站 陈秀颖 2025年上半年，中国创新药行业在政策红利与国际化突破的双重助力下迎来高光时刻，Wind数据显 示，A股创新药板块80家企业中，16家已发布中报预告。头部企业凭借技术壁垒与商业化能力实现爆发 式增长。 | 证券简称 | 预告净利润同比增长 | | 预告净利润同比增 董事长 | 总经理 | | --- | --- | --- | --- | --- | | | 上限 | 长下限 | | [交易日期] 最新 [交易日期] 最新 | | | [报告期] 今年中报 | [报告期] 今年中报 | | | | | [单位] %↓ | [单位] % | | | | 双鹭药业 | 356.24 | | 237.95 徐明波 | 徐明波 | | 全诺生物 | 332.10 | | 253.54 文永均 | 文永均 | | 步长制药 | 205.94 | | 110.88 赵涛 | #x15 | | 通化东宝 | 194.30 | | 194.30 李佳鸿 | 冷春生 | | 微芯生物 | 173.00 | | 173.00 X ...

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先 生、王忠先生及萬鈞女士。 * 僅供識別 （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於氨甲環酸注射液通過仿製藥一致性評價的公告》僅 供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 年 7 月 22 日 证券代码：601607 证券简称 ...

上海医药集团股份有限公司 证券代码：601607 证券简称：上海医药 编号：临 2025-071 关于氨甲环酸注射液通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 氨甲环酸注射液主要用于急性或慢性、局限性或全身性原发性纤维蛋白溶解 亢进所致的各种出血。弥散性血管内凝血所致的继发性高纤溶状态，在未肝素化 前，一般不用本品。 近日，上海医药集团股份有限公司（以下简称"公司"）下属上海信谊金朱 药业有限公司（以下简称"信谊金朱"）的氨甲环酸注射液（以下简称"该药品"） 收到国家药品监督管理局（以下简称"国家药监局"）颁发的《药品补充申请批 准通知书》（通知书编号：2025B03210），该药品通过仿制药质量和疗效一致 性评价。 一、该药品基本情况 药品名称：氨甲环酸注射液 剂型：注射剂 规格：5ml：0.25g 注册分类：化学药品 申请人：上海信谊金朱药业有限公司 原批准文号：国药准字 H31021856 审批结论：本品通过仿制药质量和疗效一致性评价。 二、该药品相关的信息 氨甲环酸注射液由日本第一 ...

Core Viewpoint - The special verification opinion issued by Beijing Hankun Law Firm confirms that Shanghai Wankexin Biotechnology Partnership (Limited Partnership) does not have an actual controller, which is significant for its equity changes [2][9]. Group 1: Company Overview - Shanghai Wankexin Biotechnology Partnership (Limited Partnership) is registered in the China (Shanghai) Free Trade Zone with a total capital contribution of 763.01 million RMB [3][5]. - The executing partner of Wankexin is Shanghai Shanshi Biomedical Management Consulting Co., Ltd., which holds a 0.001% partnership share [4][6]. Group 2: Equity Structure - The partnership structure includes Shanghai Shanshi Biomedical Management Consulting Co., Ltd. (0.001%), Shanghai Biomedical M&A Private Fund Partnership (Limited Partnership) (80.209%), and Shanghai Pharmaceutical (Group) Co., Ltd. (19.790%) [5][6]. - The total capital contribution of the partnership is set to change to 763.01 million RMB following the entry of a new partner, Shanghai Pharmaceutical (Group) Co., Ltd., which will contribute 151 million RMB [5][6]. Group 3: Control Structure - The executing partner, Shanghai Shanshi Biomedical, has the authority to represent the partnership and make decisions regarding partnership affairs, indicating that it acts as the controlling entity [6][9]. - Shanghai Shanshi Biomedical is jointly owned by Shanghai Shanshi Capital Management Co., Ltd. and Lubuqa Enterprise Management Consulting Partnership (Limited Partnership), each holding 50% of the shares [7][9]. Group 4: Conclusion - The verification opinion concludes that there is no single shareholder capable of controlling the shareholder meeting or board of directors of Shanghai Shanshi Biomedical, thus confirming that both Shanghai Wankexin and Shanghai Shanshi Biomedical do not have an actual controller [9][10].

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司 2024 年年度權益分派實施公告》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 年 7 月 12 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先 生、王忠先生及萬鈞女士。 * 僅供識別 证券代码：601607 证券简称：上海医药 ...

证券代码：601607 证券简称：上海医药 公告编号：临2025-070 上海医药集团股份有限公司 每股分配比例 A 股每股现金红利0.29元（含税） 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/7/17 | － | 2025/7/18 | 2025/7/18 | 差异化分红送转： 否 一、通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 6 月 26 日的2024年年度股东大会审议通过。 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 二、分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体 A 股股东。 H 股 股 东 的 现 金 分 红 有 关 情 况 详 见 本 公 司 在 香 港 联 合 交 易 所 有 限 公 司 网 ...

Core Viewpoint - Shanghai Pharmaceuticals is expected to significantly enhance its profitability due to the acquisition of a 10% stake in Shanghai Hutchison Pharmaceuticals, leading to a projected net profit of 44.50 billion yuan for the first half of 2025, representing a year-on-year increase of approximately 52% [2][3]. Financial Performance - The company anticipates a net profit of 44.50 billion yuan for the first half of 2025, an increase of 15.08 billion yuan compared to the previous year [3]. - In 2024, Shanghai Pharmaceuticals achieved a revenue of 2,752.51 billion yuan, a year-on-year growth of 5.75%, and a net profit of 45.53 billion yuan, up 20.82% [5]. - The net profit for the first quarter of 2025 was reported at 13.33 billion yuan, reflecting a decline of 13.56% year-on-year, which was reversed by the recent acquisition [4]. Cost Management - The company has successfully reduced sales expenses for two consecutive years, with a 16.11% decrease in the first quarter of 2025 [8][7]. - Sales expenses for 2023 and 2024 were 139.02 billion yuan and 127.14 billion yuan, respectively, showing a decline of 2.64% and 8.55% year-on-year [7]. R&D Investment - Research and development expenses have been on the rise for three consecutive years, with amounts of 21.12 billion yuan, 22.04 billion yuan, and 23.94 billion yuan from 2022 to 2024, reflecting growth rates of 6.29%, 4.35%, and 8.64% respectively [9]. - In the first quarter of 2025, R&D expenses were 4.97 billion yuan, showing a slight decrease of 0.88% year-on-year [10]. Shareholder Confidence - The controlling shareholder, Shanghai Industrial Group, has increased its stake in Shanghai Pharmaceuticals by 1.995%, reflecting confidence in the company's future development [2][11]. - The total shares held by Shanghai Industrial Group after the increase amount to 1.426 billion shares, representing approximately 38.461% of the total issued shares [12]. Dividend History - Since its listing, Shanghai Pharmaceuticals has distributed dividends 30 times, totaling 157.46 billion yuan, with 114.14 billion yuan from A-shares and 43.32 billion yuan from H-shares [12].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因依賴該等內容而引致之任何損失承擔任何責任。 上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd.* ( 於中華人民共和國註冊成立的股份有限公司 ) (股份代碼: 02607) 2025年半年度業績預增公告 本公告乃上海醫藥集團股份有限公司（「本公司」，連同其附屬公司合稱為「本集團」）根 據香港聯合交易所有限公司證券上市規則（「上市規則」）第 13.09(2)及 13.10B 條及證券及 期貨條例（香港法例第 571章）第 XIVA部的內幕消息條文（定義見上市規則）作出。 一、本期業績預告情況 （一）業績預告期間 2025 年 1 月 1 日至 2025 年 6 月 30 日。 （二）業績預告情況 經本公司財務部門初步測算，本公司預計 2025 年上半年度實現歸屬於母公司所有者的 淨利潤為人民幣 44.50 億元，與上年同期相比，將增加人民幣 15.08 億元，同比增長約 52%。 本公司於 ...

[Key Highlights](index=1&type=section&id=Key%20Highlights) The company anticipates a significant increase in net profit attributable to shareholders for the first half of 2025 2025 First Half Performance Forecast Overview | Metric | Amount (RMB) | Change | Year-on-Year Growth | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders (Estimated) | 4.45 billion | Increased by 1.508 billion | Approx. 52% | [Current Period Performance Forecast](index=1&type=section&id=I.%20Current%20Period%20Performance%20Forecast) This section details the company's financial performance forecast for the first half of 2025, including the reporting period and key profit estimates [Performance Forecast Period](index=1&type=section&id=(I)%20Performance%20Forecast%20Period) The performance forecast covers the financial period from January 1, 2025, to June 30, 2025 - The performance forecast period is from January 1, 2025, to June 30, 2025[3](index=3&type=chunk) [Performance Forecast Details](index=1&type=section&id=(II)%20Performance%20Forecast%20Details) The company expects net profit attributable to shareholders for the first half of 2025 to reach 4.45 billion RMB, representing an approximate 52% year-on-year increase 2025 First Half Net Profit Attributable to Shareholders Forecast | Metric | Amount (RMB) | Change | Year-on-Year Growth | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders (Estimated) | 4.45 billion | Increased by 1.508 billion | Approx. 52% | [Unaudited Statement](index=1&type=section&id=(III)%20Unaudited%20Statement) The financial data disclosed in this performance forecast is a preliminary estimate by the company's finance department and has not been audited by a certified public accountant - The data in this performance forecast has not been audited by a certified public accountant[3](index=3&type=chunk) [Prior Period Operating Performance and Financial Status](index=1&type=section&id=II.%20Prior%20Period%20Operating%20Performance%20and%20Financial%20Status) This section provides an overview of the company's operating performance and financial status for the same period in the previous year [Prior Period Net Profit Attributable to Shareholders](index=1&type=section&id=(I)%20Prior%20Period%20Net%20Profit%20Attributable%20to%20Shareholders) Net profit attributable to shareholders for the prior period (first half of 2024) was 2.942 billion RMB Prior Period Net Profit Attributable to Shareholders | Metric | Amount (RMB) | | :--- | :--- | | Net Profit Attributable to Shareholders | 2.942 billion | [Prior Period Earnings Per Share](index=1&type=section&id=(II)%20Prior%20Period%20Earnings%20Per%20Share) Earnings per share for the prior period (first half of 2024) was 0.79 RMB Prior Period Earnings Per Share | Metric | Amount (RMB) | | :--- | :--- | | Earnings Per Share | 0.79 | [Main Reasons for Performance Increase](index=1&type=section&id=III.%20Main%20Reasons%20for%20Performance%20Increase) The primary driver for the anticipated performance increase is the change in accounting treatment following the acquisition of an additional stake in Shanghai Hutchison Pharmaceuticals - The company completed the acquisition of an additional **10% equity stake** in Shanghai Hutchison Pharmaceuticals Co., Ltd. on April 25, 2025, increasing its total holding to **60%** from **50%**[5](index=5&type=chunk)[6](index=6&type=chunk) - Hutchison Pharmaceuticals' accounting method changed from equity method for a joint venture to consolidation as a subsidiary, bringing it into the consolidated financial statements[6](index=6&type=chunk) - According to accounting standards, the re-measurement of previously held equity at fair value upon gaining control due to additional investment, with the difference between fair value and book value recognized as investment income in the current period, is the main reason for the performance increase[6](index=6&type=chunk) [Risk Warning](index=2&type=section&id=IV.%20Risk%20Warning) This section highlights that the performance forecast data is preliminary and unaudited, with no major uncertainties identified as of the disclosure date - The data in this performance forecast is a preliminary estimate by the finance department and has not been audited by an accounting firm[7](index=7&type=chunk) - As of the disclosure date, the company has not identified any significant uncertainties affecting the accuracy of this performance forecast[7](index=7&type=chunk) [Other Explanatory Matters](index=2&type=section&id=V.%20Other%20Explanatory%20Matters) Investors are advised to exercise caution as the forecast data is preliminary, and the final accurate financial figures will be based on the official 2025 semi-annual report - The forecast data is preliminary, and the specific accurate financial data will be subject to the company's officially disclosed 2025 semi-annual report[8](index=8&type=chunk) - Investors are reminded to make prudent decisions and be aware of investment risks[8](index=8&type=chunk)